Arcus Biosciences, Inc.

US$18.28As of Sun 8 Nov 2026, 12:00 UTC
NYSE:RCUSHealthcare
Country USA
PE (Fwd) •••
TSR 9Y CAGR 1.98%
Div yield —
ROE (114.11%)
Biotechnology
Beta (5Y) 1.09
PE TTM —
TSR TTM (7.30%)
Mkt cap US$2.632B
ROIC (50.88%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$19
5.31%
(95.57%)
Hold 1|0|2|10|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.21
0.21
0.23
0.23
12.03%
8.57%
22.39%
25.00%
Revenue$M
192.5
192.7
192.8
189.8
0.09%
2.02%
2.08%
(1.98%)
Peers (US$2.632B)
Cap (US$)
PE
2.683B
—
Capital
TTM
5Y
10Y
Leveragex
0.131
1.265
1.245
EBIT/Intx
1.335
0.122
0.122
Own earn%
(21.03)
(96.30)
(96.14)
Sh yield%
33.62
14.72
13.18
Owners
Insiders/Inst%
0.22
79.20
Short interest%
0.74
SBC / revenue%
3.39
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
14–22
$1 testx
—
Incr. ROIC%
4